Dutch biotechnology company Crucell has secured funding from the U.S. Agency for International Development to speed up the development of malaria vaccines, Reuters reports. The funding will allow Crucell and the PATH Malaria Vaccine Initiative to conduct researches on the effectiveness of Crucell's malaria vaccines. The Dutch firm did not reveal any financial specifics.